Stockwinners Market Radar for January 13, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:09 EST Cathie Wood's ARK Investment bought 73K shares of Teladoc today

20:07 EST Cathie Wood's ARK Investment bought 214K shares of Zoom Video today

19:56 EST Citi to sell consumer bank in Indonesia, Malaysia, Thailand and Vietnam - Citi "announced it has reached agreement with UOB Group on the acquisition of Citi's consumer banking franchises in Indonesia, Malaysia, Thailand and Vietnam. The transaction includes retail banking and credit card businesses but excludes the bank's institutional businesses in all four countries. Citi remains committed and focused on serving institutional clients in these countries locally, regionally and globally. The agreement covers all related Citi staff, with approximately 5,000 consumer bank and supporting employees expected to transfer to UOB upon close of the proposed transaction. UOB will pay Citi cash consideration for the net assets of the acquired businesses, subject to customary closing adjustments, plus a premium of $690M. Upon closing, Citi expects the transaction to result in the release of approximately $1.2B of allocated tangible common equity, as well as an increase to tangible common equity of over $200M. As previously announced, Citi's exit from its consumer franchises in 13 markets across Asia Pacific and EMEA is expected to release approximately $7B of allocated tangible common equity over time."

19:19 EST Planet Labs announces successful launch of 4x Flock - Planet Labs "announced the successful launch of its 4x Flock, consisting of 44 SuperDove satellites, into orbit on a SpaceX Falcon 9 rocket. The company has established contact with all of the SuperDove satellites, many within two minutes of the final deployment, upholding Planet's record of successfully connecting with 100% of all Planet satellites launched. These 44 satellites will join Planet's existing fleet of roughly 200 satellites in orbit. Planet has now launched 127 satellites across eight launches with SpaceX, and over 500 satellites total since the company's founding 10 years ago. This marks Planet's first launch with SpaceX under their new multi-year, multi-launch rideshare agreement signed in 2021."

17:45 EST Twitter launches Spaces recording for iOS, Android devices - Twitter said that it is now allowing all Android and iOS users to record Twitter Spaces. "Hope you've gotten used to the sound of your own voice," the official Twitter Spaces account tweeted. Reference Link

17:35 EST Boston Beer falls about 5% after cutting FY21 guidance below $466

17:33 EST Boston Beer sees FY21 depletions increase 21%-22% - Sees shipments increase 15%-16%, national price increases of 2%-3%, and gross margins of 38%-40%.

17:31 EST Perma-Pipe International awarded $6M in contracts in Egypt, Saudi Arabia - Perma-Pipe International announced it has recently been awarded $6M in contracts in Egypt and Saudi Arabia. Projects will be executed in Perma-Pipe's facilities in the current quarter. The newly awarded projects are part of major infrastructure developments both in Al-Alamin, Egypt and Misk City, Saudi Arabia. The projects will utilize Perma-Pipe's fabrication and coating capabilities, and the XTRU-THERM insulation system, a spray-applied polyurethane foam jacketed with a high-density polyethylene casing.

17:06 EST Silvercorp Metals reports Q3 gold production up 38% from Q2 - Silvercorp Metals reported production and sales figures for the third quarter ended December 31, 2021. In Q3 Fiscal 2022, the company increased production to approximately 1.8 million ounces of silver, 1,100 ounces of gold, 19.0 million pounds of lead, and 8.0 million pounds of zinc, representing increases of 8%, 38%, 8%, and 7%, respectively, in silver, gold, lead and zinc over the second quarter ended September 30, 2021. For the first nine months of Fiscal 2022, the company produced approximately 5.0 million ounces of silver, 2,900 ounces of gold, 52.5 million pounds of lead, and 22.7 million pounds of zinc. Recently, strict Covid 19 quarantine policy imposed by local governments where our mines are located has caused uncertainty for workers travelling home and back during Chinese New Year holiday, which may have some impact on production for the fourth quarter.

17:01 EST Eldorado Gold reports Q4 preliminary production of 122,644 ounces of gold - Eldorado Gold is pleased to announce fourth quarter 2021 preliminary gold production of 122,644 ounces, and full year 2021 preliminary production of 475,912 ounces. Annual gold production from the company's four operating mines is at the upper end of the revised production guidance range of 460,000 to 480,000 ounces.

16:35 EST January 6 House panel subpoenas Alphabet, Meta, Twitter, Reddit - Chairman Bennie G. Thompson announced that the Select Committee has issued subpoenas to four social media companies as a part of its investigation into the January 6th attack on the U.S. Capitol and its causes. After inadequate responses to prior requests for information, the Select Committee is demanding records from Alphabet (GOOG), Meta (MVRS), Reddit, and Twitter (TWTR) relating to the spread of misinformation, efforts to overturn the 2020 election, domestic violent extremism, and foreign influence in the 2020 election. Chairman Thompson issued the following statement: "Two key questions for the Select Committee are how the spread of misinformation and violent extremism contributed to the violent attack on our democracy, and what steps-if any-social media companies took to prevent their platforms from being breeding grounds for radicalizing people to violence. It's disappointing that after months of engagement, we still do not have the documents and information necessary to answer those basic questions. The Select Committee is working to get answers for the American people and help ensure nothing like January 6th ever happens again. We cannot allow our important work to be delayed any further." The Fly notes that Reddit is working with Morgan Stanley (MS) and Goldman Sachs (GS) on an IPO, according to a Bloomberg report from last week. Reference Link

16:32 EST Weidai announces ADS ratio change - Weidai Ltd. announced that it will change the ratio of its American depositary shares representing its Class A ordinary shares from one ADS representing one Class A ordinary share to one ADS representing three Class A ordinary shares. For Weidai's ADS holders, the change in the ADS ratio will have the same effect as a one-for-three reverse ADS split. There will be no change to the company's Class A ordinary shares. The effect of the ratio change on the ADS trading price on the New York Stock Exchange is expected to take place at the open of trading on January 26, 2022. ADS holders of record on the effective date will not be required to take any action in connection with the ADS ratio change. The exchange of every three then-held ADSs for one new ADS will occur automatically with the then-held ADSs being cancelled and new ADSs being issued by the depositary bank, in each case as of the effective date for the ADS ratio change. Weidai's ADSs will continue to be traded on the NYSE under the symbol "WEI". No fractional new ADSs will be issued in connection with the change in the ADS ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold by the depositary bank and the net cash proceeds from the sale of the fractional ADS entitlements will be distributed to the applicable ADS holders by the depositary bank. As a result of the change in the ADS ratio, the ADS price is expected to increase proportionally, although the company can give no assurance that the ADS price after the change in the ADS ratio will be equal to or greater than three times the ADS price before the change.

16:30 EST Kaiser Aluminum boosts quarterly dividend 7% - Kaiser Aluminum Corporation announced that its board has declared a quarterly cash dividend of 77c per share representing a 7% increase over the prior quarter's dividend. The dividend will be payable on February 15 to shareholders of record as of the close of business on January 24.

16:19 EST Zendesk reiterates merits of proposed Momentive acquisition to shareholders - Zendesk sent a letter to stockholders commenting on its proposed acquisition of Momentive Global Inc., which was announced on October 28, 2021, and recommending their approval of the issuance of Zendesk Common Stock in connection with the transaction at the Special Meeting of Stockholders scheduled for February 25, 2022. The full text of the letter follows: "The Zendesk Board of Directors believes that Zendesk's proposed acquisition of Momentive, which was announced on October 28, 2021, will create substantial incremental long-term value for Zendesk stockholders. Zendesk's Board unanimously recommends you vote in favor of the proposal approving the issuance of Zendesk Common Stock in connection with the transaction at the upcoming Special Meeting of Stockholders, which will be held on February 25, 2022. The combination with Momentive will deliver significant benefits to Zendesk stockholders that are otherwise not attainable, including: Achievement of Zendesk's strategy of transforming Customer Relationship Management, by creating a Customer Intelligence Platform that combines Momentive's leadership in agile experience management software (spanning surveys, customer experience and market research) with Zendesk's leading customer service and sales platform to enable truly actionable insights and understanding of the customer for businesses of all sizes; A doubling of Zendesk's addressable market to $165 billion, ensuring far greater opportunity for sustained high revenue growth at larger scale; Realization of the first wave of sales-led revenue synergies of approximately $275 million by 2025, deriving primarily from a scaled and global Zendesk enterprise sales force selling Momentive's agile experience management and insights products to our customer base within the Zendesk product experience, yielding approximately $4.6 billion in combined 2025 revenue growing at a higher rate than Zendesk's forecasted smaller-scale standalone business; Significant upside to these conservative revenue synergy estimates from product-led growth, namely new product introductions, new pricing and packaging, and acceleration of Zendesk's core sales and customer service businesses due to the addition of Momentive product capabilities and data, making our offering more valuable and increasing customer spend and stickiness; The ability to drive further synergies by accelerating Momentive's enterprise growth, leveraging Zendesk's proven track record of scaling and driving adoption with enterprise customers, with additional opportunities to internationalize Momentive's offerings across Zendesk's diversified global client base and go-to-market reach; and Financial benefits from greater scale, including an expanded global talent base, significantly increased number of customer relationships, operating efficiencies that can be re-invested in growth, greater research and development resources, and more engineering expertise and technology - all of which will allow Zendesk to better serve customers and accelerate innovation. Importantly, we have increased conviction in the upside and the expected synergies noted above as a result of our preliminary integration planning work, which includes direct correspondence with customers."

16:18 EST Aspen Aerogels CFO John Fairbanks to retire, Ricardo Rodriguez to succeed - Aspen Aerogels (ASPN) announced the retirement plans of the company's CFO. John Fairbanks, Aspen's CFO, informed the company of his intent to retire after 15 years of dedicated and valuable service. Fairbanks plans to step down from his role effective April 1. Concurrently, Ricardo Rodriguez, the company's Chief Strategy Officer, will succeed Fairbanks as CFO. Prior to joining Aspen, Ricardo was a Corporate Strategy Director at Aptiv (APTV).

16:11 EST OraSure announces InteliSwab COVID-19 tests detect omicron variant - OraSure announced that its InteliSwab COVID-19 rapid tests detect the omicron variant as effectively as they detect the original SARS-CoV-2 strain and other previous variants of concern, including delta, alpha, beta and gamma. The omicron variant studies were conducted using live SARS-CoV-2 virus at an independent, third-party laboratory and showed InteliSwab detected the omicron variant at the same viral load levels, or limit of detection, as previous variants that were tested.

16:07 EST Cardiovascular Systems reports progress towards IVL systems commercialization - Cardiovascular Systems announced it has made significant progress towards the commercialization of intravascular lithotripsy systems for the treatment of calcific coronary and peripheral artery disease. Lithotripsy is a medical procedure that uses non-invasive high-pressure waves to fracture and disrupt pathologic solid masses. Lithotripsy has been used successfully for many years in the treatment of kidney and gall stones, and more recently has found application in treatment of calcified coronary and peripheral arteries. Feasibility testing of a proprietary console and associated IVL balloon catheters is complete. The CSI IVL systems are designed to improve upon the limitations of incumbent technology, allowing physicians to cross and treat more challenging atherosclerotic lesions. Commercialization of the IVL systems will be highly complementary to CSI's broader portfolio of advanced vessel preparation technologies. Scott R. Ward, Chairman, President and CEO, said, "The development of an IVL system for the treatment of coronary and peripheral artery disease will uniquely position CSI to provide the right device, for the right lesion, for all physicians. We believe the successful execution of this program will greatly expand patient access to care and CSI's overall market position in complex coronary and peripheral disease."

15:33 EST Coinbase acquires FairX, terms not disclosed - Yesterday, Coinbase announced the acquisition of FairX, a CFTC-regulated derivatives exchange or Designated Contract Market. "Through this acquisition, we plan to bring regulated crypto derivatives to market, initially through FairX's existing partner ecosystem," Coinbase said. "Over time, we plan to leverage FairX's infrastructure to offer crypto derivatives to all Coinbase customers in the US. We want to make the derivatives market more approachable for our millions of retail customers by delivering an easy-to-use user experience that Coinbase is known for." The acquisition is subject to customary closing conditions and reviews, and is expected to close in Coinbase's first fiscal quarter.

14:50 EST Supreme Court allows healthcare worker vaccination rule to stand - The Supreme Court has ruled that vaccine requirements can stand for medical facilities that take Medicare or Medicaid payments, arguing that the Secretary of Health and Human Services has it within his power to mandate that, in order to receive Medicare and Medicaid funding, participating facilities must ensure that their staff-unless exempt for medical or religious reasons-are vaccinated against COVID-19. In the ruling, the high court states: "First, we agree with the Government that the Secretary's rule falls within the authorities that Congress has conferred upon him... Moreover, the Secretary routinely imposes conditions of participation that relate to the qualifications and duties of healthcare workers themselves... We accordingly conclude that the Secretary did not exceed his statutory authority in requiring that, in order to remain eligible for Medicare and Medicaid dollars, the facilities covered by the interim rule must ensure that their employees be vaccinated against COVID-19." Makers of COVID-19 vaccines approved for use in the U.S. include Pfizer (PFE) and BioNTech (BNTX), Moderna (MRNA), and Johnson & Johnson (JNJ). Reference Link

13:39 EST Gap launches collectible NFT experience - Yesterday, Gap announced the global launch of its first collection of non-fungible tokens, or NFTs, to bring its brand and iconic product to new and existing customers in a rapidly evolving digital ecosystem. For this launch, the brand is introducing a gamified digital experience celebrating creatives and giving customers the unique opportunity to own a limited edition, collectible Gap hoodie. For this release, Gap is collaborating with Brandon Sines, the artist behind Frank Ape, for a limited edition drop. "With this partnership with Gap, the creative cycle has come full circle as it allows me to express the beautiful messages of Frank Ape while collaborating with one of the most classic brands in history," said Sines. "I cannot wait to share the physical and digital pieces we've been working on with Gap and Frank fans worldwide." As part of the company's commitment to "do the right thing for the planet," it has chosen to leverage Tezos, an open source blockchain, to create the customer experience. Tezos uses a more energy efficient approach to secure its network, allowing it to operate with minimal energy consumption and a low carbon footprint. Reference Link

13:19 EST Rocky Mountain Chocolate appoints Elisabeth Charles as board chair - Rocky Mountain Chocolate Factory announced the appointment of Elisabeth Charles as Chair of the Board. Ms. Charles succeeds Jeffrey Geygan who has served as interim Chair since October 2021, providing key stability and leadership to the RMCF Board of Directors after the election of the reconstituted Board at the recent annual meeting of stockholders. Mr. Geygan will remain with the Company as a director and member of both the Compensation Committee and Audit Committee. The Board unanimously approved the appointment of Ms. Charles as Chair, and she will continue to serve on the Compensation Committee and Audit Committee. In addition, RMCF has engaged executive search firm O'Keefe & Partners to continue a comprehensive search process and support RMCF in bringing on its next CEO. As previously announced, Bryan Merryman, current interim President and CEO, will step down from this position upon the appointment of a successor.

13:00 EST Prothena expects to start producing data from PRX005 trial this year

13:00 EST Prothena CEO anticipates potential IND filing for Alzheimer's vaccine next year

12:50 EST Planet Green Holdings Corp trading resumes

12:26 EST Canadian Pacific responds, says CN proposal 'built on series of factual errors' - Canadian Pacific Railway (CP) issued a statement in response to CN's (CNI) Notice of Intent to file a Responsive Application asking the STB force a divestiture of KCS's lines east of Kansas City as part of the Surface Transportation Board's regulatory review of CP's proposed combination with Kansas City Southern (KSU), stating: "CN's proposal is built on a series of factual errors or misstatements. KCS's Kansas City-Springfield line is not 'parallel' to CP's line between Kansas City and Chicago. KCS's line does not reach Chicago, and contrary to CN's misleading statements, KCS's line is not part of a through route to Chicago in conjunction with CN. In fact, there is no direct connection between KCS and CN today at Springfield, and historic interchange volumes reflect the absence of any actual service here. Only four cars were interchanged by KCS at Springfield with CN in 2020 and 133 cars interchanged with CN in 2019. As part of CPKC, these lines will grow along with CPKC. CP's proposed pro-competitive combination with KCS is about growth. A future CPKC will not downgrade any lines, these included. Instead, CPKC will maintain existing levels of service on these lines and will not re-route traffic away from these lines, contrary to CN's assertions. In fact, the route from Kansas City to St. Louis and the other assets CN wants the STB to force CP to divest are important parts of the combined CPKC growth story providing new, competitive single-line routes connecting CP's network with customers and port facilities in St. Louis, and connections to eastern carriers. CP anticipates an increase of traffic on this corridor of 30 percent. CP will be responding to any formal CN request for conditions in the pending STB proceeding at the appropriate time."

12:00 EST Elastic falls -9.4% - Elastic is down -9.4%, or -$10.44 to $100.60.

12:00 EST Virgin Galactic falls -16.2% - Virgin Galactic is down -16.2%, or -$2.00 to $10.37.

12:00 EST Sonendo rises 14.2% - Sonendo is up 14.2%, or $1.02 to $8.20.

11:59 EST Dun & Bradstreet to make operational changes, refunds to settle FTC charges - To settle Federal Trade Commission charges that it engaged in deceptive and unfair practices, Dun & Bradstreet has agreed to an order requiring "substantial changes in the firm's operations that will benefit small- and mid-sized businesses," the FTC announced. Under the proposed order, D&B will also provide refunds to certain businesses that purchased the company's products in the belief that using the products would improve their business credit scores and ratings, the FTC stated. "A faulty D&B credit report can be a huge burden on a small business, raising costs and choking off opportunities. This order arms businesses with new tools to ensure a fair shake, stops D&B from profiting illegally from businesses' pain, and returns funds to firms that got fleeced," said Samuel Levine, Director of the FTC's Bureau of Consumer Protection. Reference Link

11:32 EST Bluejay Diagnostics reports 90 subjects completed in rapid IL-6 COVID test trial - Bluejay Diagnostics reported that it has completed 90 subjects in the prospective multicenter clinical study addressing rapid IL-6 test for COVID-19 patients with critical care. "This study performs unique rapid on-site measurement using patient whole blood and positions the company to move forward with multiple initiatives," Bluejay stated in a press release. "This phase of our clinical studies is key not only for the progress towards commercialization, but to also demonstrate the competitive advantages that the Symphony System may bring to medical care. With these studies, Bluejay is well positioned to move forward with several initiatives that will highlight the importance of IL-6 testing for the triage of patients with suspected Sepsis as well as other related conditions such as 'Cytokine Storm Syndrome' in COVID-19 patients. The early identification of this vulnerable patient population can help guide medical care to institute preventative treatments to improve patient prognosis. Furthermore, using IL-6 as an early warning indicator can assist healthcare systems to sequester critical resources in time to save lives," said Neil Dey, Bluejay's CEO.

11:09 EST Navient in $1.85B settlement with state AGs over student loan servicing - Pennsylvania Attorney General Josh Shapiro announced that Navient will provide relief totaling $1.85B to resolve allegations of "widespread unfair, deceptive, and abusive student loan servicing practices and abuses in originating predatory student loans." Attorney General Shapiro co-led the litigation and negotiation of the settlement with Washington, Illinois, Massachusetts, and California. This settlement was joined by attorneys general in Arizona, Arkansas, Colorado, Connecticut, the District of Columbia, Delaware, Florida, Georgia, Hawaii, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New Mexico, New York, North Carolina, Ohio, Oregon, Rhode Island, South Carolina, Tennessee, Vermont, Virginia, West Virginia and Wisconsin. Attorney General Shapiro filed the settlement as a proposed Consent Judgment today in the U.S. District Court for the Middle District of Pennsylvania. The settlement will require court approval. Under the terms of the settlement, Navient will cancel the remaining balance on nearly $1.7B in subprime private student loan balances owed by nearly 66,000 borrowers nationwide. In addition, a total of $95M in restitution payments of about $260 each will be distributed to approximately 350,000 federal loan borrowers who were placed in certain types of long-term forbearances, Shapiro reported. This settlement, joined by a coalition of 39 attorneys general, resolves claims that since 2009, "despite representing that it would help borrowers find the best repayment options for them, Navient steered struggling student loan borrowers into costly long-term forbearances instead of counseling them about the benefits of more affordable income-driven repayment plans," the AG said in a press release. Reference Link

10:53 EST Delta Air Lines 'getting ready' to restart contract talks with pilots

10:25 EST Dave Inc trading resumes

10:20 EST Dave Inc trading halted, volatility trading pause

10:18 EST Delta optimistic int'l markets will reopen this spring as restrictions lift

10:14 EST Delta Air Lines sees FY22 capcity 90% recovered vs. 2019

10:09 EST Delta Air Lines announces profit-sharing payment for all elligible employees - Delta said earlier: "To recognize the extraordinary efforts of our employees through the pandemic, we will make a special profit-sharing payment to eligible employees in February 2022, based on the adjusted pre-tax profit earned during the second half of 2021.This adjustment allows investors to better understand and analyze our recurring cost performance and provides a more meaningful comparison of our core operating costs to the airline industry."

10:07 EST Delta Air Lines CEO expects pre-tax losses in January, February

10:06 EST Delta CEO sees omicron cases peaking in U.S. over next few days

10:05 EST Delta 'confident' pace of travel recovery will resume December trajectory

10:03 EST Caesars Sportsbook named sports betting partner of Michigan State Athlethics - Michigan State University Athletics, MSU Sports Properties and Caesars Entertainment announced a multi-year partnership to make Caesars Sportsbook the Official and Exclusive Sports Betting Partner and iGaming Partner of MSU Athletics. "Michigan State has a proud tradition of excellence and partnering with an internationally recognized brand in college athletics is a great opportunity for us," said Eric Hession, Co-President of Caesars Digital. "The Spartan fan base and alumni network is passionate and well-established across the country. We look forward to building upon our connection with them while strengthening the legacy we hold in the state of Michigan and advancing scholarship opportunities through this partnership."

10:01 EST Sirius XM unit acquires Cloud Cover Media, terms not disclosed - SiriusXM announced that its subsidiary, Sirius XM Radio, has acquired Cloud Cover Media. Cloud Cover Media offers Cloud Cover Music, a music for business service, and employs business management, music programming, licensing, and software development teams. Cloud Cover Music's easy-to-use solutions and robust tech platform allow businesses to deliver music, with customized audio messaging if desired, to create the desired atmosphere for their prospects, customers, and clients. The Cloud Cover Music team will continue to be led by Vice President and General Manager Mark Lehman.

10:00 EST E2open falls -7.0% - E2open is down -7.0%, or -68c to $9.02.

10:00 EST Virgin Galactic falls -14.4% - Virgin Galactic is down -14.4%, or -$1.78 to $10.59.

10:00 EST TSMC rises 9.0% - TSMC is up 9.0%, or $11.92 to $144.15.

09:47 EST Elastic falls -7.2% - Elastic is down -7.2%, or -$8.02 to $103.02.

09:47 EST Virgin Galactic falls -11.7% - Virgin Galactic is down -11.7%, or -$1.45 to $10.92.

09:47 EST KB Home rises 10.0% - KB Home is up 10.0%, or $4.25 to $46.63.

09:33 EST Co-Diagnostics JV CoSara receives clearance for SARAGENE test in India - Co-Diagnostics announced today that CoSara Diagnostics, its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization in India to manufacture and sell its SARAGENE Human Papillomavirus High-Risk Real-Time PCR test as an in vitro diagnostic.

09:31 EST Sinclair Broadcast's DSG renews digital distribution rights agreement with NBA - Sinclair Broadcast Group announced that its subsidiary, Diamond Sports Group, has renewed its extended market and digital distribution rights agreement with the National Basketball Association. Under the agreement, DSG's Bally Sports Regional Networks are permitted to offer streaming content, including live games, on an authenticated and direct-to-consumer basis, to the local territories of 16 NBA teams. Teams included in the agreement are the Atlanta Hawks, Charlotte Hornets, Cleveland Cavaliers, Dallas Mavericks, Detroit Pistons, Indiana Pacers, LA Clippers, Memphis Grizzlies, Miami Heat, Milwaukee Bucks, Minnesota Timberwolves, New Orleans Pelicans, Oklahoma City Thunder, Orlando Magic, Phoenix Suns, and San Antonio Spurs.

09:19 EST Rhythm expects to initiate three Phase 3 trials of setmelanotide in 2022 - Rhythm expects to initiate three additional Phase 3 trials of setmelanotide in 2022, including: The pivotal Phase 3 EMANATE clinical trial, which is expected to initiate in the first quarter of 2022. EMANATE, a randomized, double-blind, placebo-controlled trial, will evaluate setmelanotide in five independent sub-studies in patients with obesity due to: a heterozygous variant of the POMC/PCSK1 genes or LEPR gene, certain variants of the SRC1 gene or the SH2B1 gene, or PCSK1 N221D deletions within the MC4R pathway. The company estimates these populations represent approximately 100,000-200,000 people in the United States. The Phase 3 pediatric trial evaluating daily setmelanotide in patients between the ages of 2 and less than 6 years of age with rare genetic diseases of obesity, which is expected to initiate in the first quarter of 2022. Rare genetic diseases of obesity often present early in life, and Rhythm's genetic testing programs have identified many patients with these diseases who are younger than 6 years old. If successful, VENTURE could enable earlier therapeutic intervention, with the potential to change the overall trajectory of disease and transform the lives of these patients and their families. This trial is a multi-center, one-year, open-label trial in pediatric patients with obesity due to biallelic POMC, PCSK1 or LEPR deficiency or a clinical diagnosis of BBS with genetic confirmation. The primary efficacy endpoint is a responder analysis, based on the proportion of patients who experience a decrease from baseline in BMI Z of greater than or equal to0.2. A second Phase 3 trial to evaluate the weekly formulation of setmelanotide, which is expected to initiate in the second half of 2022. This de novo trial will be a randomized, double-blind clinical trial in patients with BBS who live outside the United States. The company expects to enroll 40 patients, randomized 1:1 to receive 30 mg of setmelanotide or placebo once weekly for 18 weeks. Following the 18-week treatment period, patients will continue on treatment, or crossover from placebo to active therapy, for an additional 14 weeks. The primary efficacy endpoint is the mean change from baseline in body weight after approximately 18 weeks of once weekly dosing.

09:18 EST Rhythm Pharmaceuticals doses first patients in weekly switch trial - Rhythm announced that it has dosed the first patients in the Phase 3 switch trial evaluating a weekly formulation of setmelanotide in patients 6 years of age and older with a rare genetic disease of obesity who are currently taking the daily formulation of setmelanotide. Rhythm's weekly formulation of setmelanotide is designed to offer patients a more convenient dosing regimen. It is being evaluated in a Phase 3 randomized, double-blind switch trial in patients with obesity due to biallelic or heterozygous POMC, PCSK1 or LEPR genetic variants or a clinical diagnosis of BBS with genetic confirmation, who were previously enrolled in Rhythm's long-term, open-label daily setmelanotide extension trial. Rhythm expects to enroll 30 patients, randomized 1:1 to receive once-weekly setmelanotide and once-daily placebo, or once daily setmelanotide and once weekly placebo for 13 weeks. Following the 13-week randomized treatment period, patients will crossover to an open-label, 13-week study in which all patients will receive once-weekly setmelanotide. The primary efficacy endpoint is a responder analysis, based on the proportion of patients with no weight gain defined as a change of 5 percent or less from baseline to week 13.

09:17 EST Rhythm Pharmaceuticals doses first patients in DAYBREAK trial - Rhythm Pharmaceuticals announced the first patient has been dosed with setmelanotide, the company's melanocortin-4 receptor agonist, in the Phase 2 DAYBREAK clinical trial to treat the severe obesity and hyperphagia potentially caused by a genetic variant that impairs function of the MC4R pathway. The company also announced the dosing of the first patient in the Phase 3 trial evaluating a switch from the daily to a novel weekly formulation of setmelanotide. The DAYBREAK trial is designed to evaluate setmelanotide in patients who carry a confirmed variant in one or more of 31 genes with strong or very strong relevance to the MC4R pathway, which regulates the body's energy balance, including appetite, energy expenditure and body weight. Results from the DAYBREAK clinical trial have the potential to identify future patient populations and to inform the design of future registrational studies to support setmelanotide label expansion. DAYBREAK is a two-stage, double-blind, placebo-controlled trial that will be conducted at more than 75 trial sites across 12 countries. Rhythm plans to enroll approximately 500 patients with severe obesity and a variant in one of 31 genes relevant to the MC4R pathway. Any patients who demonstrate a clinically meaningful response to setmelanotide at the end of a 16-week, open-label run-in period will be eligible to enter the second stage of the study. Stage 2 will be a 24-week, double-blind, placebo-controlled withdrawal study, in which patients will be stratified into genetically defined cohorts and randomized 2:1 to receive setmelanotide or placebo. The primary efficacy endpoint is a responder analysis based on the proportion of patients treated with setmelanotide who achieve a clinically meaningful weight reduction threshold at the end of treatment compared to patients treated with placebo. Each genetically defined cohort can read out results independently.

09:13 EST Braze continues global expansion with presence in Canada and France - Braze announced it plans to expand its global footprint to include Toronto, Canada and Paris, France, with recruitment beginning immediately for positions in the greater Paris area as well as across Canada. The investment in these new countries enables Braze to offer localized support for its existing customers in both markets, including KFC Canada, Tim Hortons, Dailymotion, and Lydia. Braze also believes this expansion will allow the company to capitalize on growing market opportunities and increase strategic partnerships. Additionally, Braze is further expanding its US footprint with a new office location in Austin, and an expanded office space for its Chicago-based team. "The global nature of modern digital businesses means that Braze has always had a global customer footprint. Our first overseas expansion dates back to 2016 when we opened in London and we have since added offices in Singapore, Chicago, Tokyo, and Berlin as our customer count has grown," said Bill Magnuson, cofounder and CEO of Braze. "Looking ahead into 2022, we are very excited to continue improving our ability to serve our global customers and to invest in the communities where they thrive by opening new offices in France, Canada, and the Central United States."

09:11 EST Pentwater sends letter to Rio Tinto board calling for corporate governance moves - On January 6, Pentwater Capital Management sent the a letter to Ngaire Woods, member of the Board of the Directors of Rio Tinto (RIO) outlining continued corporate governance failures at Rio Tinto. On January 7 . Rio Tinto's attorney responded that neither Ms. Woods nor any other Rio Tinto board member would respond to Pentwater regarding the ongoing corporate governance breaches that Rio is inflicting upon Turquoise Hill (TRQ). The letter said in part: " Dear Ms. Woods, am writing to you once again in your capacity as a Board member of Rio Tinto. My goal is to convince you to stop further harming Oxford's reputation by continuing to sanction Rio Tinto's complete breaches of appropriate corporate governance with respect to its controlled subsidiary Turquoise Hill. I had hoped that you would respond to my previous letter dated November 8, 2021. I assumed that as the Dean of Oxford's Blavatnik School of Government, you would be interested in learning as much as possible about the corporate governance failures and egregious misconduct committed by Rio Tinto. Since you are one of Rio Tinto's newest Board members, you could have been an advocate for positive change. Instead, you completely ignored our letter, and now you implicate yourself, as Rio Tinto is in the process of once again making a mockery of appropriate corporate governance at Turquoise Hill. It is no wonder Oxford's own are publicly criticizing Oxford, and specifically your school, for accepting donations from a rogue corporate entity like Rio Tinto."

09:09 EST Vir Biotechnology launches new antibody research initiative - Vir Biotechnology announced an expansion of its partnership with the Bill & Melinda Gates Foundation to include the advancement of innovative platform technologies in the development of broadly neutralizing antibodies designed to provide a "vaccinal effect" for the treatment of HIV and prevention of malaria. This novel program combines Vir's extensive immunologic and virologic expertise with the Gates Foundation's long-standing global health leadership to address two of the world's most challenging infectious diseases. "Vir's partnership with the Bill & Melinda Gates Foundation has been a formative and essential part of our company history beginning with our T-cell vaccine program targeting HIV and tuberculosis. This expanded collaboration into a second platform technology supports our shared goal of developing innovative solutions for prevention and treatment of global infectious diseases," said George Scangos, Ph.D., chief executive officer of Vir Biotechnology. The new initiative includes a clinical proof-of-concept trial designed to evaluate the potential impact of broadly neutralizing antibodies engineered to inhibit viral replication and spread in people infected with HIV, as well as their ability to confer a vaccine-like effect that could be applicable to durable antiretroviral therapy-free suppression of HIV.

09:08 EST PetDx, IDEXX expand access to OncoK9 cancer liquid biopsy test for dogs - PetDx announced a collaboration with IDEXX Laboratories to significantly broaden access to canine cancer liquid biopsy testing. OncoK9, PetDx's pioneering liquid biopsy test for the detection of cancer in dogs, will be available later this month to all veterinary customers, in the United States and Canada, served by IDEXX Reference Laboratories.

09:07 EST Thorne HealthTech and Mitsui to form Thorne Asia joint venture - Thorne HealthTech has agreed to form a joint venture with Mitsui called Thorne HealthTech Asia. Thorne Asia will drive awareness of, and expand access to, Thorne's leading solutions and approaches to address health and wellbeing across Asia. Thorne Asia will promote and provide Thorne's diagnostics, analytics, and supplement offerings online, as well as through medical and retail providers, and utilize Mitsui's business professional healthcare and consumer retail expertise and relationships in the region. Mitsui has been a long-term partner and investor in Thorne HealthTech.

09:06 EST Radius Health completes business adjustment - Radius Health, has completed an adjustment of its business. The catalyst for the changes was the completion of three pivotal trials during the second half of 2021. Those trial readouts included: abaloparatide male study, ATOM, on October 18, elacestrant, EMERALD, on October 20, and abaloparatide transdermal system, wearABLe, on December 8. Both the ATOM and EMERALD studies were positive, having achieved statistical significance vs. all primary endpoints. The wearABLe study failed to meet its pre-determined primary endpoint. Ongoing U.S. regulatory work is proceeding for the abaloparatide male indication, with the sNDA submission expected in Q1, 2022. The company is also advancing elacestrant along the regulatory pathway in the U.S. and Europe.

09:06 EST Rubicon acquires CIVIX, terms not disclosed - Rubicon Technologies announced that it has acquired CIVIX, a routing software and solutions company based out of Freiburg, Germany. The acquisition expands and enhances the routing capabilities of Rubicon's flagship software products for municipal and private fleets, RUBICONSmartCity and RUBICONPro, while also helping to drive Rubicon's growth into additional international markets. Founded in 1999, CIVIX is the developer of the market-leading FleetRoute route optimization and strategic planning software and associated technologies for data collection, in-cab navigation, dispatching, tracking, performance monitoring, and messaging. FleetRoute's geographic information system and cloud-based route optimization software is used to solve the most complex high-density routing problems through advanced network algorithms developed specifically for the municipal services, utility, and street surveying industries. With customers in North America, Europe and the Middle East, FleetRoute's book of business includes local governments, councils and municipalities; private companies and corporations; public utilities; and federal and regional government agencies. In addition to CIVIX's full suite of route optimization services, it also provides operational consulting services as part of its offering. As part of the acquisition, the President of CIVIX, Dr. Paul Patterson, and his team have joined Rubicon.

09:04 EST Nielsen's The Gauge report shows streaming at 33% share around Christmas - Nielsen announced that The Gauge, its monthly total TV and streaming snapshot, revealed that streaming in the U.S. reached a new all-time weekly high of over 183 billion minutes of video in December 2021, giving over-the-top platforms a record-breaking 33% share of total TV viewing during the week of Christmas. According to The Gauge, aggregate viewing for streaming platforms surpassed the previous-high of 178 billion minutes streamed during Thanksgiving week in November 2021. Prior to that, the 160 billion minutes streamed during March 2020 was the highest total. The overall percentage share for streaming remained flat from the previous month at 28%. Cable viewing continued to account for the largest percentage as measured by The Gauge, with just over 37% total share of viewership. The Gauge also shows that broadcast viewing dropped one share point, while the "Other" category, which includes video on-demand content, cable set top box streaming, gaming, and DVD usage, gained 1.6% share on the strength of video gaming's premiere season. Additionally, The Gauge has now expanded the granularity of usage data, displaying an additional decimal point to better reflect and delineate month-to-month changes in viewing share.

09:03 EST Lexicon oultines potential value drivers for 2022 - Lexicon Pharmaceuticals is outlining major potential value drivers for 2022 at this morning's presentation at the 40th Annual J.P. Morgan Healthcare Conference. Lexicon submitted a new drug application to the U.S. Food and Drug Administration in December 2021 for the approval of sotagliflozin to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent visits for heart failure in adult patients with type 2 diabetes. In the NDA, Lexicon is seeking a potentially unique label addressing recent and worsening heart failure, based on the landmark SOLOIST-WHF study. Importantly, the proposed NDA label encompasses patients across the spectrum of left ventricular ejection fraction. If approved, Lexicon expects to commercially launch sotagliflozin in the United States in the second half of 2022. Lexicon will outline additional details and information about its commercial strategy in today's presentation. In addition, Lexicon is looking forward to near-term results from two Phase 2 proof-of-concept studies of LX9211 in neuropathic pain. LX9211 is a potent, orally delivered, selective small molecule inhibitor of adaptor associated kinase 1, a novel target first identified using Lexicon's technology platform as having promise for the treatment of neuropathic pain. Results from these two studies are expected in the first half of 2022.

09:02 EST Verizon announces BlueJeans Studio, new event production platform - Verizon Business announced BlueJeans Studio, a new event production platform. "Virtual events have become a fundamental part of every business strategy, whether that be for individual creators looking to build brand visibility or for enterprise teams working on communication, training or lead generation initiatives," said Chris Lewter, VP and GM, BlueJeans by Verizon. "With the addition of Studio to provide premium production services, combined with our leading event assist support team, BlueJeans Events is the optimal solution to help brands of all sizes transform their virtual events to really wow their audiences."

08:59 EST Auddia teams with with advertiser-supported podcast firm PodcastOne - Auddia announced a new partnership with PodcastOne , a subsidiary of LiveOne. PodcastOne, a network of 200+ podcasts, will select four podcasts within the initial phase of the partnership and create digital feed content for each new episode. In addition to content creation, podcast hosts will promote the Vodacast app and the supplementary content through native mentions during episodes. "The Vodacast platform is a wonderful complement to our other programming. It taps into our passionate fan base and gives them a deeper experience with their favorite shows," said Kit Gray, President, PodcastOne. "We are always looking for new ways to engage our audience and collaborate with advertisers; this partnership accomplishes both missions." Auddia CEO, Michael Lawless added, "PodcastOne is a titan in the space. Their content is beloved by fans, and we're excited to bring our unique platform of podcaster tools, plus the ability for users to go even deeper into the stories they love, to PodcastOne's loyal audiences. We view this relationship as another example of our vision of continued podcaster partnerships and content development within the Vodacast app coming to fruition."

08:56 EST Edesa Biotech receives approval from Health Canada to test EB05 - Edesa Biotech reported that the company has received approval from Health Canada to test its monoclonal antibody candidate, designated EB05, as a rescue therapy for critically ill patients in the Phase 3 part of a Phase 2/3 clinical study.

08:55 EST American Battery delivers first Tonopah Flats lithium samples for analysis - American Battery Technology Company has completed drilling of its first set of several sampling locations and submitted the subsurface samples collected from their Tonopah Flats Lithium Exploration Project for high throughput screening analysis. These samples were collected from their initial secured 305 lode mining claims, located in Big Smoky Valley near Tonopah, Nev. Given the promising results of initial surface samples of the original 305 claims, combined with the confirmed geological representative characteristics and surface expressions of adjacent claims, ABTC commenced an additional exploratory subsurface sampling program to potentially further develop this resource where the sample results will be used to understand the extent of the deposit in footprint, depth, and the grades of the lithium. The company will continue with additional exploratory drilling while thorough analyses of these initial samples are underway. The ABTC Tonopah Flats Lithium Exploration Project currently encompasses the exploration, sampling, and analysis of 427 unpatented lode mining claims covering approximately 8,540 acres of land. The company will continue conducting geological mapping, sampling, geochemical analysis, and proprietary extraction trials to characterize these high potential resources and to quantify the performance of its internally developed lithium extraction and manufacturing operations.

08:52 EST Teekay LNG closes acquisition by Stonepeak, to rebrand as Seapeak - Teekay LNG Partners announced that it completed the previously announced acquisition of the Partnership by investment vehicles managed by Stonepeak. All common units will convert into the right to receive $17.00 per common unit in cash, subject to deductions of applicable withholding tax. The common units, which trade on the New York Stock Exchange under the ticker symbol "TGP", will be suspended from trading today and delist from the NYSE within 10 days. The Partnership's Series A and B preferred units, which trade on the NYSE under the ticker symbols "TGP PR A" and "TGP PR B", respectively, will remain outstanding and continue to trade on the NYSE. With the acquisition complete, the Partnership will rebrand as Seapeak. The Partnership intends to convert to a limited liability company during the first quarter of 2022, at which time it will change its name to Seapeak LLC and change its Series A and B preferred units ticker symbols to "SEAL PR A" and "SEAL PR B", respectively. As Seapeak, the Partnership will launch a new organizational vision and identity, reflecting intentions to renew and grow its primary business of owning and operating LNG carriers, and to explore potential adjacencies

08:48 EST QuantumScape, Fluence Energy to collaborate on stationary storage - QuantumScape (QS) and Fluence Energy (FLNC) announced a multi-year agreement to introduce solid-state lithium-metal battery technology to stationary energy storage applications. The companies will collaborate on what they believe to be a first-of-its-kind solution to incorporate QuantumScape's battery technology into Fluence stationary energy storage products as specific technical and commercial milestones are met.

08:42 EST Muscle Maker adds franchise sales, training team to support expansion plans - Muscle Maker announced the addition of three new team members to support Pokemoto's growth strategy: Mike Spavelko, Vice President of Franchise Sales; Kimberly Tauch, Franchise Sales and Development Manager and Jennifer Holden, Director of Corporate and Franchise Training. The three new hires bring a combined 80+ years of restaurant growth and development experience to the company via multiple franchise brands.

08:41 EST ReShape Lifesciences appoints Michael Bordainick as SVP, Commercial Operations - ReShape Lifesciences (RSLS) announced the appointment of Michael Bordainick as its Senior Vice President, SVP, Commercial Operations. "In this newly created role, as part of the Company's next phase of operational growth Bordainick will be responsible for strengthening the strategic development and executional efficiencies of the sales and marketing teams," the company said. Bordainick joins Reshape from Alcon (ALC), where he served as Global Vice President of Marketing.

08:38 EST vTv Therapeutics announces corporate presentation highlighting TTP399 - vTv Therapeutics is sharing its updated corporate presentation highlighting its lead program TTP399, a novel oral liver-selective glucokinase activator, as a transformative treatment in the reduction of hypoglycemic episodes for the global diabetes population. Key Takeaways include: Hypoglycemia is common in people with type 1 diabetes and can occur quickly, with symptoms including sweating, nausea, coordination problems, headaches and even seizures. TTP399 may be used as a once-daily, oral adjunctive therapy in a $16B global insulin market for the reduction of hypoglycemic episodes. TTP399 has been tested in almost 600 patients to date with no evidence of diabetic ketoacidosis. vTv has worldwide rights to TTP399 with global pivotal trials anticipated in 2022. vTv is actively seeking to raise non-dilutive capital through licensing TTP399 in regions outside of North America and Europe. vTv is also actively seeking licensing deals for HPP737 and other assets.

08:37 EST Brooklyn ImmunoTherapeutics announces 18 patents issued in 2021 - Brooklyn ImmunoTherapeutics announces that 18 new patents were issued and 17 new patent applications were filed in 2021. The intellectual property is owned by Factor Bioscience and exclusively licensed to Brooklyn for various fields of therapeutic use. The newly-issued patents encompass those covering the Company's mRNA-based cellular reprogramming and gene editing technology, as well as nucleic acid delivery using Brooklyn's ToRNAdo lipid nanoparticle technology. Many of the newly-issued patents are directed to compositions and methods for reprogramming somatic cells to pluripotent stem cells and using mRNA-based methods to direct gene editing. Other newly-issued patents are directed to a novel LNP that efficiently delivers nucleic to cells both in vitro and in vivo. The new patents have been issued in the United States, Australia, Japan, Korea, Hong Kong, and eight European countries, including France and Great Britain and have expiry dates that extend to 2032 or beyond.

08:36 EST Data Storage provides 2021 year-end business update - Data Storage Corporation provided a 2021 year-end business update. 2021 Achievements: Commenced trading on the Nasdaq Capital Market; Completed merger with Flagship Solutions, LLC, a leading provider of IBM solutions, managed services and cloud solutions worldwide; Opened the Canadian marketplace by placing IBM equipment in two Tier 2 data centers for IaaS and disaster recovery; Entered a managed services model partnership with Precisely, a global leader in data integrity software; Announced several significant appointments to senior management; With Flagship acquisition and new hires, grew headcount from 29 to 60 increasing headcount by over 100%; Grew subscription and recurring revenue by 57% for the first nine months of 2021; Maintaining a 94% renewal rate on existing long term client contracts; $17m total contract value sales proposals; $16m+ in remaining contract value; Tier 3 data centers in the USA and Canada; Concluded 2021 with a multi-million dollar contract with one of the nation's most recognized professional sports teams. Chuck Piluso, CEO of Data Storage Corporation, commented, "2021 was a monumental year for Data Storage Corporation that has laid the foundation for meaningful growth for years to come, both operationally and financially. Notably, we completed the merger with Flagship Solutions that significantly expanded our services and quickly proved to be highly synergistic with our existing IBM operations, ultimately positioning us as a leading, one-stop provider for multi-cloud IT solutions. We have already identified numerous cross-selling opportunities, allowing us to realize solid revenue growth since completion of the merger. Moreover, we anticipate continued growth and additional opportunities within this market as the IBM on-premise server market has only begun to transition to the cloud in the last few years. Specifically, of the one million plus virtual IBM Power servers, only 15% have begun the migration to the cloud. We believe this represents a multi-billion-dollar global addressable market and we are ideally positioned to capitalize on this trend. Additionally, we continue to execute on our business growth strategy by expanding our offerings, which have provided new and valuable opportunities-much like our partnership with Precisely, a global leader in data integrity and cyber security software solutions. The addition of Precisely's expanded solutions within a cloud environment has allowed us to offer an even more robust and full-featured offering that addresses the most common IT security exposure issues, including ransomware. These solutions have become increasingly important as more and more organizations are migrating to the cloud and are in need of critical security features that protect information, data privacy, and adhere to compliance standards. We also entered into a partnership with Able-One, filling a vital need for cloud services in Canada among businesses that run IBM Power systems on IBM i, AIX and Linux operating systems. This partnership begins to open up new markets in Canada and added two new Tier 3 enterprise-level data centers, while expanding the DSC's North American footprint. To date, we have completed meaningful acquisitions and entered into strategic partnerships that provide us more inclusive features and services for our clients, demonstrating our commitment to offering customers the most cutting-edge and comprehensive technologies. As a result of our strategic initiatives in 2021, DSC has a remaining contract value on subscription services alone of greater than $16 million with a 94% contract renewal rate and over $17 million in total outstanding contract proposals-a historic high for our company. We continue to see an uptick in interest in our solutions and a desire from the user community to find out how to migrate their IBM systems to the cloud, as well as layer additional cloud infrastructure solutions such as disaster recovery, cyber security and data analytics. We have a strong balance sheet with approximately $12.9 million of cash and cash equivalents as of September 30, 2021, enabling us to execute on our growth strategy, as well as explore opportunistic acquisitions that would further enhance our offering. Overall, we are proud to report that the activities we undertook throughout the year have proven successful, resulting in more than 400 customers, 16 new channel partners, and a growing employee base, including a number of key senior appointments in 2021. We believe with the meaningful progress achieved, we are well positioned for significant growth in 2022 and beyond given our established and scalable global business model that we believe will sustain Data Storage as a leader in the industry for years to come."

08:34 EST Mullen Automotive provides update on the electric vehicle program - Mullen Automotive announces an update for Mullen Shareholders on the Mullen FIVE EV Crossover Program and the Mullen EV Cargo Van Program. Mullen FIVE Program: "The Mullen engineering team, along with our supplier partners, are making good progress to complete the first fully functional vehicles for both the Mullen FIVE Launch edition and Mullen FIVE RS, high performance edition," the company said. The time frame for the first fully functional and drivable vehicles, including the FIVE RS, is currently on track for Q3 2022. Mullen EV Cargo Van Program: The Mullen EV Cargo Van program continues making solid progress at Mullen's Advanced Manufacturing and Engineering Center, AMEC, located outside Tunica, Mississippi, with completion of the cargo van assembly process. Despite the global issues with Covid and shipping delays, the company is on track to deliver first units to fleet order customers in Q2 2022.

08:33 EST Assure Holdings reports 2,100 remote neurology managed cases performed in 2021 - Assure Holdings announced that its remote neurology business, which launched in 2021, performed more than 2,100 remote neurology managed cases during the year. This included 1,222 in the fourth quarter of 2021, which exceeded the Company's forecasted range of 1,000 to 1,200 during the period. Assure currently has four supervising practitioners performing remote neurology services. The Company is actively recruiting to fill additional positions and expects to continue ramping-up staffing for this function over the course of 2022 and beyond.

08:32 EST Predictive Oncology reports results from AI cancer drug evaluation - Predictive Oncology reported the preliminary results of its Discovery 2021 program, announcing that its Helomics subsidiary's evaluation demonstrated their proprietary Artificial Intelligence program CoRE, combined with their tumor profile data and matched ovarian cancer samples, could identify potential new chemotherapy drug uses. These drugs are not currently approved for ovarian cancer, but, with further study, could be used for ovarian cancer treatment following clinical trial and regulatory approval. "PeDAL leads to a better selection of drugs, matching the different cancer types to the patients associated with those cancers and potential treatments, improving the scientific and clinical success of drug development. This also translates to millions of dollars in reduced development costs for our future partners. PeDAL can now deliver a proven system that efficiently drives drug response experiments and pulls patient-centric data into the discovery process," said J. Melville Engle, CEO, Chairman of Predictive Oncology.

08:23 EST Hyzon Motors discloses receipt of SEC subpoena related to Blue Orca claims - In a regulatory filing on Wednesday, Hyzon Motors disclosed that it had received a subpoena from the Securities and Exchange Commission for production of documents and information, including related to the allegations made in the report issued by Blue Orca Capital. The company said it is cooperating with the SEC.

08:20 EST Credicorp's BCP obtains 'Strong' rating for sustainable financing framework - In line with Credicorp's corporate sustainability strategy, Banco de Credito del Peru has developed a Sustainability Financing Framework that establishes the parameters and processes that BCP and Mibanco must observe to launch financing instruments for green or social purposes, including bonds and commercials papers issued through public or private placements, loans and repos. On January 12th, S&P Global Ratings has announced its decision to grant a rating of "strong" to this framework after finding that it is aligned with international sustainability standards; has clearly defined the criteria for eligible projects; and incorporates a commitment to transparently report on the use and impact of proceeds. With this decision, BCP becomes the first bank in Latin America to obtain a strong rating for its sustainable financing framework.

08:18 EST Robinhood CFO sells $302.5K in common stock - In a regulatory filing yesterday evening, Robinhood disclosed that its CFO Jason Warnick sold 20K shares of common stock in a total transaction size of $302.5K on January 10th.

08:14 EST Seven Hills Realty Trust boosts dividend 67% to 25c per share - Seven Hills Realty Trust announced it has raised its quarterly cash distribution on its common shares by 10c per share, or 67%, to 25c per share, $1.00 per share per year. The distribution declared today will be paid to SEVN's common shareholders of record as of the close of business on January 24 and distributed on or about February 17.

08:13 EST Enphase Energy expands battery storage in Colorado - Enphase Energy announced that Enphase installers in Colorado have seen increased deployments of the Enphase Energy System, powered by IQ Microinverters and IQ Batteries, across the state. "With an average of more than 300 sunny days per year, Colorado has tremendous solar potential," said Dave Ranhoff, chief commercial officer at Enphase Energy. "The IQ Battery paired with clean solar energy enables residents to take full advantage of the region's plentiful renewable energy by generating and storing it to use when they need it most. We are pleased to be partners with so many great installers in Colorado and provide our best-in-class technology solutions to families across the state."

08:12 EST aTyr Pharma announces USAN, INN selected efzofitimod as name for ATYR1923 - aTyr Pharma announced that the United States Adopted Names, USAN, Council and the World Health Organization's, WHO, International Nonproprietary Name, INN, Expert Committee have selected the nonproprietary name efzofitimod for ATYR1923, a novel immunomodulator targeting neuropilin-2, in clinical development for pulmonary sarcoidosis, a major form of interstitial lung disease. "aTyr is working to develop a new class of medicines based on extracellular tRNA synthetase biology, and the assignment of the nonproprietary name efzofitimod for ATYR1923 is an important step as we continue to advance this potentially disease-modifying immunomodulator to its next stage of development," said Sanjay Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.

08:10 EST Home Bancshares announces proposed $200M subordinated notes offering - Home BancShares announced that it plans to offer, subject to market and other offering conditions, $300M of its fixed-to-floating rate subordinated notes due 2032 in an underwritten public offering. The Company intends to use the net proceeds for general corporate purposes, which may include, but are not limited to, the repayment of its outstanding subordinated notes and subordinated debentures, the payment of outstanding subordinated debentures to be assumed upon completion of its acquisition of Happy Bancshares, investments at the holding company level, providing capital to support the growth of Centennial Bank and its business, repurchases of its common shares and the payment of the cash consideration components of future acquisitions. Piper Sandler & Co. is serving as sole book-running manager for the offering.

08:10 EST CommScope, ViacomCBS partner on content distribution migration - CommScope (COMM) and ViacomCBS (VIAC) announced that ViacomCBS launched FAVE and migrated its DABL and select Showtime linear channels from satellite to Content Delivery Network, or CDN, IP distribution using the CommScope DigiCipher Streaming system. The migration represents the first ViacomCBS services to be fully transitioned from satellite to CDN IP-leveraging existing CDN IP infrastructure for service distribution to CBS broadcast stations, DABL affiliates, and Showtime MVPDs throughout their U.S. footprint instead of traditional satellite delivery.

08:08 EST Proterra battery technology to power Vicinity Motor electric buses, trucks - Vicinity Motor (VEV) and Proterra (PTRA) announced a new collaboration to power Vicinity's electric transit buses and work trucks with Proterra's industry-leading battery technology. Under a new, multi-year supply agreement, Proterra battery systems will power the Vicinity Lightning 28-foot electric transit bus and Vicinity's strip chassis platform to support several commercial vehicle configurations such as utility trucks, shuttle buses, and box trucks. Proterra contracted to supply Vicinity with battery systems to power a minimum of 600 Vicinity commercial electric vehicles through 2024. The Proterra Powered Vicinity Lightning vehicle is expected to begin production in the third quarter of 2022.

08:07 EST ESS and PGE in pact to test and demonstrate 3MWh ESS Energy Center platform - ESS Tech announced that it has entered into an agreement with Portland General Electric PGE in Oregon to test and demonstrate the ESS Energy Center platform. The 3 MWh Energy Center is expected to come online in mid-2022 and be used to demonstrate multiple use cases, including frequency response, contingency reserve, voltage and VAR support, demand response and resource optimization. The project will be located on land adjacent to ESS' factory headquarters in Wilsonville, Oregon. "Building a reliable, affordable clean energy future requires us working together with industry innovators," said Darren Murtaugh, Senior Manager of Grid Edge Solutions at PGE. "Our collaboration with ESS on the Energy Center will provide important learnings on our path to meeting our greenhouse gas emission reduction targets."

08:06 EST iSpecimen expands support of COVID-19 research - iSpecimen announced the expansion of its supplier capabilities with the addition of a reference lab in New York to support commercial and government customers focused on COVID-19 research, including analyzing the Omicron and Delta variants. The reference lab, a recent addition to the iSpecimen supplier network, has the capacity to sequence hundreds of COVID-19 positive swabs per week, providing data that is crucial in the fight against the virus. This lab is sequencing the most recent swabs to identify new variants of COVID-19 as the virus continues to progress globally.

08:05 EST II-VI signs renewable energy contract in China - II-VI Incorporated announced that it has signed a major renewable energy contract in China. The II-VI site in Wuxi represents approximately 50% of the company's footprint in China and about 20% of its global footprint by area. Over the next four years, this facility will become the largest II-VI site to be powered with 100% renewable electricity. "This purchase agreement includes approximately 167 million kWh of renewable electricity over the next four years, thereby avoiding nearly 92,000 metric tons of CO2 emissions cumulatively over this period," said Gary Lin, Senior Vice President, Operations, Photonic Solutions Segment. "This demonstrates our commitment to increase the sustainability in our energy supply across our global footprint."

08:04 EST Sterling National Bank announces participation in USDF Consortium - Sterling National Bank announced its participation in the USDF Consortium, an association of FDIC-insured financial institutions, whose objective is to advance the adoption and interoperability of a bank-minted stablecoin, USDF. USDF will be established on the Provenance Network, a public blockchain that supports real-time payment capabilities and will facilitate faster, cheaper, more secure money movement. USDF seeks to address many of the regulatory concerns raised related to non-bank minted stablecoins. The USDF Consortium has been formed to build a network of banks to facilitate the compliant transfer of value on the blockchain, removing friction in the financial system and unlocking the financial opportunities that blockchain technology can provide to users. The Consortium is doing the foundational work to allow banks to leverage blockchain technology to drive responsible innovation and growth.

08:03 EST Nikola's Tre BEV approved by CARB as zero-emission vehicle - Nikola announced that its Nikola Tre battery-electric vehicle has been deemed eligible for the Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project program by the California Air Resources Board. With this approval, purchasers of the Nikola Tre BEV can now qualify for an incentive valued at $120,000 per truck, helping to reduce the total cost of ownership for any purchaser operating in the state of California.

08:02 EST Denali Therapeutics announces FDA clinical hold on DNL919 IND application - Denali Therapeutics announced that after the close of business on Wednesday, January 12, 2022, the company was informed via e-mail communication from the U.S. Food and Drug Administration that the DNL919 Investigational New Drug application has been placed on clinical hold. The FDA indicated they will provide an official clinical hold letter to Denali in approximately 30 days. Denali plans to provide additional updates pending discussion with the FDA.

07:42 EST Saputo president, COO Kai Bockmann steps down - Saputo announced a change in its senior management structure with the retirement of Kai Bockmann. Effective immediately, Bockmann is stepping down as President and COO and will be leaving the Company on March 4, 2022. Carl Colizza, President and COO, North America, and Leanne Cutts, President and COO, International and Europe, who reported to Bockmann, will report to Lino Saputo, now serving as Chair of the Board, President and CEO.

07:41 EST Vitalhub enters multi-year licensing agreement with Stafford and Stoke-on-Trent - VitalHub is pleased to announce a multi-year licensing agreement of wholly-owned subsidiary Transforming Systems' proprietary SHREWD Resilience and COVID-19 modules with Staffordshire and Stoke-on-Trent Integrated Care Systems. The ICS has agreed to a multi-year licensing agreement, which will span over three-years, and be one of Transforming Systems' largest sales to date. The finalization of this agreement is a testament to the Company's increasingly large footprint in the UK healthcare system. Transforming Systems will be deploying the SHREWD Resilience and SHREWD COVID-19 modules across the ICS network. The ICS's mandate is to elevate their healthcare delivery by closely managing their resources, performance, and delivery. By providing a real-time picture of the entire health system in one place and reducing the administrative burden of current manual processes across the health network, SHREWD systems will play an instrumental role in supporting their endeavours. SHREWD's real-time decision-making tools will empower the ICS in their pursuit of improving the efficiency of care delivery by enabling operational visibility across the system.

07:39 EST Auxly reports 'continued national leadership' in Cannabis 2.0 product sales - Auxly Cannabis Group reports its "continued national leadership" in Cannabis 2.0 product sales in 2021, securing a 15% share of the growing category, as confirmed by Headset Canadian Insights data. The company said, "The Company's #1 spot is driven by its dominance in the vapour segment, where it achieved 23% national market share for the year, with all three of its vape brands - Back Forty, Kolab Project and Foray - securing a spot in the top 5 selling brands across the country. The Company also saw a steady quarter-over-quarter growth in total market share, achieving its strategic objective of reaching the #5 LP position in overall sales by the end of 2021. As one of the few Canadian LPs to gain market share throughout the year, Auxly successfully captured 7.4% of the total market in Q4 2021, securing a new leading position among the top performing LPs in the country. Leading the growth in market share was the Company's expansion into dried flower and pre-rolls, which still account for over 75% of national cannabis sales, and remains a key growth driver for Auxly going into the new year where it will leverage the added support of its newly acquired 1.1 million sq. ft. greenhouse cannabis cultivation facility in Leamington, ON."

07:37 EST Quipt provides bi-weekly status update on management cease trade order - Quipt Home Medical is providing this bi-weekly update on the status of the management cease trade order granted on December 30, 2021 by its principal regulator, the British Columbia Securities Commission, under National Policy 12-203 - Management Cease Trade Orders, following the Company's announcement on December 16, 2021 that it was unable to file its audited annual financial statements and management discussion & analysis for the financial years ended September 30, 2021 and 2020, and the CEO and CFO certificates, all as required by National Instrument 51-102 and National Instrument 52-109 on or before December 29, 2021, as required under applicable securities laws. as previously announced. In addition, the Company received a letter from the Nasdaq Listing Qualifications department on January 12, 2022, notifying the Company that because the Company has not yet filed its Form F-40 related to its fiscal year ended September 30, 2021, that is no longer complies with Nasdaq's Listing Rules for continued listing. Under the Rules, the Company has sixty calendar days to submit a plan to regain compliance and after submitting a plan, Nasdaq can grant an exception of up to one hundred eighty calendar days from the Form 40-F filing's due date, or until June 27, 2022, to regain compliance. The Company continues to work diligently and expeditiously with its auditors and expects to file the Documents as soon as possible but no later than January 28, 2022. Upon filing of the documents in Canada, the Company intends to immediately file its Form 40-F with the SEC thereby regaining compliance with the Rules prior to the sixty-day deadline for the Company to submit a plan to regain compliance. The Company announced on January 3, 2022, that its application for a MCTO under NP 12-203 had been approved by the BCSC. The MCTO does not affect the ability of investors to trade in the securities of the Company. On December 16, 2021, the Default Announcement disclosed that the Company was filing an application seeking a MCTO from the BCSC because it was likely to miss its filing deadline of December 29, 2021 to file the Documents. The delay in filing the Documents is due, in part, to the accelerated deadline for the Company to complete the Documents as a result of its listing its Common Shares for trading on the Nasdaq Capital Market and the expedited basis in which the Company's auditors had to complete the audit. The MCTO restricts trading in securities of the Company by management until such time as the Documents have been filed by the Company and the MCTO is no longer in effect. The MCTO does not affect the ability of other securityholders to trade in the securities of the Company.

07:35 EST Achilles Therapeutics announces 2022 key upcoming milestones - Achilles has a number of key milestones slated for 2022. These include: Acceptance of the US IND for head and neck squamous cell carcinoma in the first quarter of 2022. Reporting data in the second half of 2022 from a cohort of patients with higher-dose cNeT as monotherapy in both NSCLC and melanoma. Reporting data in the second half of 2022 from a cohort of melanoma patients with higher-dose cNeT in combination with a PD-1 inhibitor. Initiating the Company's Tumor Archiving Program in the first half of 2022. Expanding manufacturing capacity in the UK at the Cell & Gene Therapy Catapult. Establishing a Research & Development facility in the US.

07:32 EST BridgeBio announces clinical collaboration with Amgen to study BBP-398 - BridgeBio Pharma announced a non-exclusive clinical collaboration with Amgen (AMGN) to evaluate the combination of BBP-398, a potentially best-in-class SHP2 inhibitor, with LUMAKRAS, a KRASG12C inhibitor, in patients with advanced solid tumors with the KRAS G12C mutation. The Phase 1/2 study will include a dose escalation period followed by dose expansion and optimization, and is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of BBP-398 in combination with LUMAKRAS. Under the terms of the non-exclusive collaboration, BridgeBio will sponsor the study and Amgen will provide a global supply of LUMAKRAS.

07:27 EST Ascot Resources announces assay results at Premier Gold Project - Ascot Resources is pleased to announce additional assay results from the 2021 exploration drill program at the Company's Premier Gold Project. This release contains the remainder of assay results from exploration drilling at the Day Zone, as well as assays from one hole drilled at the Woodbine target and one at the Boneyard near the Premier mill. Highlights from the drill results include: 58.60 g/t Au and 24.8 g/t Ag over 1.90m from a depth of 35m in hole P21-2384 at the Day Zone. This is in an area where Ascot is internally evaluating preliminary stope shapes for potential extraction early in the mine life at Big Missouri. 11.22 g/t Au and 19.1 g/t Ag over 9.35m from a depth of 158m in hole P21-2336 at the Day Zone, including 16.51 g/t Au and 29.8 g/t Ag over 5.66m. This intercept was drilled from a pad approximately 400m south from the initial discovery holes in 2020. 5.48 g/t Au and 9.8 g/t Ag over 4.80m from a depth of 188m in hole P21-2387 at the Boneyard near the Premier mill. This hole provides further evidence of mineralization continuing beyond the western limb of the Northern Light deposit.

07:24 EST Wesdome Gold Mines reports Q4 Eagle River gold production 24,630 ounces - Wesdome Gold Mines announces fourth quarter and full year 2021 production results and 2022 guidance. Production from the Eagle River Complex in Q4 2021 totaled 62,374 tonnes at an average grade of 12.6 grams per tonne and a recovery rate of 98% to produce 24,630 ounces of gold, putting full year 2021 production at 265,267 tonnes at an average grade of 12.2 gpt to produce 101,403 ounces, near the high end of our 2021 production guidance of 92,000 - 105,000 ounces. At Kiena, Q4 production was 38,000 tonnes at an average grade of 14.1 gpt and a recovery rate of 98% to produce 16,929 ounces. Total production for the year at Kiena was 68,470 tonnes at an average grade of 10.4 gpt at a recovery rate of 98% to produce 22,440 ounces, also near the high end of our guidance range of 15,000 - 25,000 ounces. 2021 Highlights: Eagle River underground gold production of 228,759 tonnes at an average grade of 13.8 gpt at a recovery rate of 98% to produce 99,120 ounces. Total Eagle River Complex production of 101,403 ounces, the first time in the mine's history production exceeded 100,000 ounces. Mishi gold production of 36,508 tonnes at an average grade of 2.4 gpt to produce 2,283 ounces. Kiena Mine embarked on a construction and mining ramp up as per the May 2021 Pre-Feasibility study - fully funded from cash flow. Combined revenue from gold sales of $262.6 million. Published Kiena Pre-Feasibility Study; IRR 98%. Discovered new high grade Footwall Zone at Kiena Complex. Initial sill development and production on the Falcon 7 Zone and discovery of North Contact Zone at Eagle River. Monetized Moss Lake via vend-in transaction with Goldshore Resources for aggregate consideration of $57M including $12.5M upfront in cash and 30% of issued and outstanding shares at closing

07:20 EST Pacific Biosciences appoints Lara Toerien as VP, General Manager for Americas - PacBio (PACB) appoints Lara Toerien, Ph.D., as Vice President, VP, and General Manager for the company's Americas region. Lara will be responsible for leading and developing PacBio's commercial organization within North and South America while furthering its growth and market presence throughout the region. She most recently served as Senior Regional Sales Director, Northeast for Illumina (ILMN), where she spent 16 years in the sales organization.

07:18 EST View Inc. smart windows to be installed at The Artise - View (VIEW) announced its smart windows will be installed at The Artise, a 605,000-square-foot Class-A office building in Bellevue, Washington. The building has been entirely preleased to Amazon (AMZN). The Artise is Schnitzer West's third project with View, following Denver's The Current, River North and Civica Cherry Creek. View Smart Windows will be installed throughout the building. "Buildings of the future will be focused on people and the planet, with every aspect designed to optimize occupant health and sustainability," said Sri Venkat, Vice President at View. "We're thrilled to once again partner with Schnitzer West to accelerate the digital transformation of the workplace and deliver a state-of-the-art office where Amazon employees will thrive."

07:16 EST Xos appoints Mike Chaffins as VP of Supply Chain - Xos (XOS) announced Mike Chaffins has joined the company as Vice President, VP, of Supply Chain. Chaffins will report to Chief Operating Officer and Co-Founder, Giordano Sordoni. Chaffins was the global head of supply chain for Nikola (NKLA), leading the sourcing, landing, and certifying of parts for electric and hybrid vehicles

07:14 EST Gilat Satellite captures greater share of maritime market in new deal - Gilat Satellite Networks announced that the company has captured a greater share of the maritime market in a new deal with a Eurasian satellite service provider that is set to enable expanded maritime connectivity in the region. Gilat's SkyEdge II-c system will be used to deliver connectivity for vessels at sea, primarily providing broadband communication for commercial fishing and maritime transport market segments. "Our penetration into the maritime market in Eurasia further fortifies Gilat's global mobility leadership in the satellite communication market," said Barak Lerer, Gilat's Regional Vice President for EMEA & Eurasia. "Maritime is an important strategic focus market for Gilat and we are proud of this achievement, capturing more of the market and enabling satellite communication for fishing, maritime transport, and other industries in Eurasia."

07:12 EST Gritstone first patient enrolled in Phase 2/3 GRANITE, reports Phase 1/2 data - Gritstone bio announced that the first patient has been enrolled for inclusion in the Phase 2/3 GRANITE-CRC-1L trial. The trial evaluates the individualized neoantigen vaccine GRANITE in combination with immune checkpoint blockade for the first line maintenance treatment of newly diagnosed patients with metastatic, microsatellite-stable colorectal cancer, MSS-CRC. This trial has registrational intent and has been discussed previously with the FDA. Additionally, the company reported updated overall survival data from its Phase 1/2 GRANITE trial evaluating individualized immunotherapy in combination with nivolumab and ipilimumab in patients with advanced solid tumors, specifically end-stage metastatic MSS-CRC. Patients with MSS-CRC who experienced a molecular response continue to have an OS advantage compared to those patients who did not have a molecular response.

07:11 EST Yamana Gold maintains longer-term 10-year outlook - The Company expects to release its three-year production and 2022 cost guidance on February 17, 2022, along with its full year 2021 operating results, financial results and as noted, year-end 2021 mineral reserves and mineral resources. Beyond its three-year guidance, the Company maintains its longer-term 10-year outlook first announced on January 25, 2021. The Company initially provided and continues to maintain its 10-year outlook, in addition to its three-year guidance, to transparently demonstrate the sustainability, longevity and growth of the business based on what is currently in its portfolio without reliance on exploration successes or business acquisitions. With its 2021 year-end mineral reserves and mineral resources, the Company expects to demonstrate the robustness of its operations to maintain a production base of at least 1 million GEO. In addition to this sustainable platform, the Company has significant growth attributable to the advancement of Wasamac, the ongoing optimization of the Jacobina phased expansion and the advancing Odyssey project at Canadian Malartic. Several other projects and optimizations across its portfolio also present the opportunity for further growth and significant value creation. Yamana maintains its attractive positioning with its current portfolio of assets able to not only maintain its current production platform for the next decade, but also to demonstrate meaningful growth, capitalizing on its organic growth pipeline and strong geological upside across sites.

07:10 EST Endeavour Silver to acquire Pitarrilla Project from SSR Mining for $70M - Endeavour Silver (EXK) has entered into a definitive agreement to purchase the Pitarrilla project in Durango State, Mexico by acquiring all of the issued and outstanding shares of SSR Durango from SSR Mining Inc. (SSRM) for total consideration of $70M and a 1.25% net smelter returns royalty. Pitarrilla is a large undeveloped silver, lead, and zinc project located 160 kilometres north of Durango City, in northern Mexico. Dan Dickson, Endeavour's Chief Executive Officer said, "We now have a tremendous growth pipeline, which in addition to Pitarrilla includes the Terronera and Parral projects, in a country where we have extensive experience and expertise. While Terronera is the next project to be developed, we anticipate that Pitarrilla will be a significant asset in our portfolio and may take priority over the advancement of Parral." Total consideration payable on closing of the Transaction is $70M, consisting of $35M in Endeavour shares and a further $35M in cash or in Endeavour shares at the election of SSR Mining and agreed to by Endeavour. SSR Mining will retain a 1.25% NSR Royalty on Pitarrilla. Endeavour will have matching rights to purchase the NSR Royalty in the event SSR Mining proposes to sell it. Any cash component will be satisfied with cash on hand.

07:07 EST Salarius announces acquisition of DeuteRx's targeted protein portfolio - Salarius Pharmaceuticals announced a definitive agreement with DeuteRx to acquire an oral, small molecule targeted protein degradation portfolio. The acquisition includes a lead drug candidate that Salarius has renamed SP-3164, formerly DRX-164, the related patent family, including issued composition of matter patents, and the opportunity to develop additional undisclosed cancer-fighting assets in the targeted protein degradation space. Under the terms of the agreement, DeuteRx will receive from Salarius an upfront payment consisting of $1.5M in cash and 1 million shares of restricted stock. Based upon the success of SP-3164, DeuteRx is also entitled to receive up to $53M in future clinical and regulatory event-driven milestone payments and sales achievement milestone payments of up to $135M, as well as escalating royalties on net sales. Additionally, DeuteRx is eligible to receive event-driven clinical, regulatory and sales achievement milestone payments of up to $84M, as well as escalating royalties on net sales, for each of two future products.

07:04 EST Can-Fite says Piclidenoson destroys pathological skin cells - Can-Fite BioPharma announced that pre-clinical studies with skin cells, modeling psoriasis in humans, show that Piclidenoson, the company's drug candidate for the treatment of psoriasis, destroys pathological skin cells. The company's scientists reported that in a cell culture of human HaCaT cells, incubated with Piclidenoson, cell apoptosis was induced with an increase in the caspase protein, known to mediate apoptotic responses. Piclidenoson is a novel, first-in-class, A3 adenosine receptor agonist A3AR small molecule, orally bioavailable drug with a favorable therapeutic index demonstrated in Phase II clinical studies. The Company expects to announce topline results during Q1 2022 from its randomized, double blind, active and placebo-controlled study currently being conducted in Europe, Israel, and Canada. The study's primary endpoint is the proportion of patients who achieve a PASI score response of greater than or equal to75% PASI 75 vs. placebo at week 16. Secondary endpoints include non-inferiority to Otezla in weeks 16 and 32. Patients enrolled in the study have been selected based on their over-expression of A3AR, Can-Fite's therapeutic target. "The data shown in our lab experiments are important and support the mechanism of action of Piclidenoson and supply additional support for the drug effect. We are encouraged by the positive interim analysis data reported last year based on 200 patients' data and hope that it will be reproducible and that psoriasis patients will benefit from safety and long term relief from the symptoms of psoriasis," stated Can-Fite CEO Dr. Pnina Fishman.

07:04 EST SSR Mining sells Pitarrilla Project to Endeavour Silver for $127M - SSR Mining (SSRM) has entered into a definitive agreement to sell its Pitarrilla project in Durango, Mexico to Endeavour Silver (EXK) for total consideration of up to $127M. Total consideration consists of $35M in cash, $35M in Endeavour Silver shares, and a 1.25% net smelter return royalty on the Pitarrilla property currently estimated by SSR Mining to be valued at up to $57M. In addition, Endeavour Silver has committed to incur a minimum of $10M in exploration expenditures on the Pitarrilla project over a five-year period following closing of the transaction. The cash and equity components of the consideration totaling $70M will be paid upon closing of the transaction. On closing, SSR Mining will hold approximately 5% of the outstanding shares of Endeavour Silver. Closing of the transaction is expected to occur in the first half of 2022. The transaction is expected to be accretive to SSR Mining on an NAV per share basis. SSR Mining has realized in excess of $235M in aggregate consideration over the past 7 months. Pitarrilla is a silver, lead, and zinc project located in the State of Durango, Mexico. Endeavour Silver is currently advancing the Terronera mine project towards a development decision, pending financing and final permits, and exploring its portfolio of exploration and development projects in Mexico, Chile and the U.S.

07:03 EST EVgo platform reaches 2M registered users - PlugShare, a part of the EVgo family since mid-2021, announced that its platform has reached over 2M registered users globally. This triple-digit growth in user registrations comes on the heels of the platform surpassing over 1M new app downloads over the course of 2021, further solidifying PlugShare's position as the platform used by EV drivers for locating and selecting public chargers.

07:02 EST Amgen, AstraZeneca: Tezspire now available for shipment in U.S. - Amgen (AMGN) and AstraZeneca (AZN) announced tezspire is now available for shipment to wholesalers in the U.S. Tezspire was approved by the U.S. FDA on December 17, 2021 for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.

06:56 EST Griffon announces HSR clearance for acquisition of Hunter Fan Company - Griffon announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired in connection with its proposal to acquire Hunter Fan Company. The transaction is expected to close the week of January 24.

06:38 EST Delta Air Lines sees Q1 capacity 83%-85% - Sees Q1 fuel price per gallon $2.35-$2.50. Sees Q1 CASM up 15%. Sees Q1 gross capital expenditures $1.6B.

06:24 EST AstraZeneca to present data in liver, biliary tract and prostate cancers at ASCO - AstraZeneca "will present new data in liver, biliary tract and prostate cancers illustrating its ambition to revolutionise cancer care at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium and the 2022 ASCO Genitourinary Cancers Symposium. A total of 35 abstracts from AstraZeneca will be featured across the two meetings. There will be two oral presentations at ASCO GI taking place 20 to 22 January, and an additional two oral presentations at ASCO GU taking place 17 to 19 February." Reference Link

06:21 EST Booster with AstraZeneca's Vaxzevria shows higher response to COVID variants - The company states: "Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial showed that Vaxzevria, when given as a third dose booster, increased the immune response to Beta, Delta, Alpha and Gamma SARS-CoV-2 variants, while a separate analysis of samples from the trial showed increased antibody response to the Omicron variant. The results were observed among individuals previously vaccinated with either Vaxzevria or an mRNA vaccine. A separate Phase IV trial reported in a preprint with The Lancet on SSRN showed that a third dose of Vaxzevria substantially increased antibody levels following a primary vaccine series with CoronaVac. These data add to the growing body of evidence supporting Vaxzevria as a third dose booster irrespective of the primary vaccination schedules tested. The company is submitting these additional data to health authorities around the world given the urgent need for third dose boosters."Reference Link

06:13 EST Coinbase to give employees four 'recharge' weeks off this year, CPO Brock says - Coinbase is giving employees four "recharge" weeks off this year, Chief People Officer L.J. Brock said in a blog post. The move will see nearly the entire company shut down to avoid work piling up. The goal of the time off is to balance out the company's "intense work culture" and long hours, Brock said, adding that "Four weeks of coordinated recharge time might sound like a lot of time off for a company in hypergrowth, but given the intensity of our work throughout the year, we think this is the best way to ensure our pace is sustainable for the long term." Reference Link

06:07 EST Radware names Guy Avidan as CFO, effective February 18 - Radware (RDWR) announced the appointment of Guy Avidan as its new CFO, effective February 18. Avidan joins Radware from Kornit Digital (KRNT). Before serving as president at Kornit, Guy was CFO of Kornit Digital for six years, leading Kornit to its initial public offering on Nasdaq.

05:12 EST Rackspace Technology partners with Digivante in EMEA - Rackspace Technology announced it is partnering with Digivante, which provides digital performance analysis, and continuous website and application testing services, to deliver Artificial Intelligence, or AI-powered application testing for Rackspace Technology customers in EMEA.